Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 387

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 387
---
. The award defined in the Deferred Share Right Agreement is in accordance with consultancy agreement, dated September29, 2021, between Heritas Argentina and the CEO. Under the terms of the Deferred Share Right Agreement, the Parent will transfer a specified number of shares to the CEO in exchange for services rendered to the Group until 12months post -closing. Pursuant to the agreement, the CEO will receive 513,750 ordinary shares of the Parent, which will be transferred one year after the Closing. Additionally, 78,750 ordinary shares may be transferred based on the achievement of certain performance milestones, also one year after the Closing. In addition, in the event that the CEO ceases to be employed by the Parent or its affiliates prior to the one -yearanniversary of the Closing, the deferred share rights will vest immediately. In the event of resignation or termination for cause prior to the one -yearanniversary of the Closing, the deferred share rights will be forfeited. 203 Deferred Share Right Agreements with Key Employees In October 2024, the Parent, at the sole discretion of the shareholders of the Parent, entered into Deferred Share Right Agreements (“DSRs”) with three key employees of Heritas Argentina (each a “Key Employee”). These agreements were structured to incentivize and retain critical talent identified as essential for OmnigenicsAI and Heritas Argentina’s success following the Closing. Under the terms of these DSRs, (i) each employee will receive a deferred share grant of 30,000shares of the Parent, for a total of 90,000shares to be granted; (ii) the shares will vest and be transferred one year after the Closing (the “Vesting Date”), provided the Key Employee remains employed with the Parent, or its affiliates, including OmnigenicsAI and Heritas Argentina; and in the event of resignation or termination for cause before the Vesting Date, the shares will be forfeited. Conversely, in the case of termination without cause, the rights will vest immediately. No additional share -basedincentives have been provided. Share Option Plan The Company has no share option plan in place for employees. 204 OmnigenicsAI Management’s Discussion and Analysis of
Financial Condition and Results of Operations The following discussion and analysis provide information which our management believes is relevant to an assessment and understanding of OmnigenicsAI’s results of operations and financial condition. This discussion and analysis should be read together with the section of this proxy statement / prospectus entitled “Selected Historical Financial Information